In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1
Human Gene Therapy · 2026
DOI: 10.1177/10430342261460681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Jenny A Greig und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, Gene Editing, Alcohol Oxidoreductases, Genetic Therapy. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Precision BioSciences.
Abstract (Originalsprache)
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder that leads to kidney and liver failure. PH1 is caused by a mutation in the alanine glyoxylate aminotransferase ( AGXT ) gene, which encodes a key metabolic enzyme that converts glyoxylate to glycine in the liver. Inability to metabolize glyoxylate leads to oxalate overproduction, yielding insoluble calcium oxalate crystals; accumulation of these crystals leads to progressive organ failure. Here, we used a novel, minimally disruptive genome-editing approach to disrupt the mechanism of action of hydroxyacid oxidase 1 (HAO1), an upstream enzyme in the glyoxylate metabolic pathway. Successful gene editing and disruption of the HAO1 gene is expected to increase levels of glycolate, a harmless intermediate of the glycine metabolic pathway, thereby preventing the formation of calcium oxalate crystals. We intravenously administered an adeno-associated virus (AAV) vector expressing the M1HAO1 meganuclease to both wild-type and Agxt −/− mice, a mouse model of PH1. We observed >30% editing of HAO1 in Agxt −/− mice, correlating with a dose-dependent increase in serum glycolate levels. At the highest dose tested, urine glycolate levels increased by 79%, with a concomitant 75% decrease in urine oxalate levels. We also evaluated in vivo targeting in rhesus macaques injected with AAV expressing two different versions of the HAO1 meganuclease. Dose-dependent editing of hepatic DNA and RNA was achieved, and serum glycolate levels changed in a manner consistent with successful liver editing; additionally, the treatment was well tolerated. Our results indicate that AAV-delivered meganucleases can effectively target HAO1 in mice and nonhuman primates to achieve high levels of HAO1 gene editing. Moreover, increased glycolate levels in serum indicate that this intervention significantly impacts the HAO1-mediated glycolate-to-glyoxylate pathway. These data suggest that this approach may represent an effective treatment for PH1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: James M Wilson
Förderung
- Precision BioSciences
Zitieren
APA
Greig, J. A., Breton, C., Smith, M. K., Furmanak, T., Bell, P., Clark, P., & Wilson, J. M. (2026). In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1. Human Gene Therapy. https://doi.org/10.1177/10430342261460681
Vancouver
Greig JA, Breton C, Smith MK, Furmanak T, Bell P, Clark P, et al. In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1. Human Gene Therapy. 2026. doi:10.1177/10430342261460681
BibTeX
@article{Greig2026,
author = {Greig, Jenny A and Breton, Camilo and Smith, Melanie K and Furmanak, Thomas and Bell, Peter and Clark, Peter and Wilson, James M},
title = {In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261460681}
}
EUVIMED